WHO is ending the hydroxycholorquine trial for COVID-19
The World Health Organizationsays it is ending a trial into whether anti-malaria drug hydroxychloroquinehelps patients hospitalised with COVID-19.
- It has "accepted the recommendation" from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir.
- The decision won't affect those receiving the drugs before potential exposure to the
coronavirusor shortly afterward.
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir "produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care."
The agency adds that while there was no "solid evidence" of increased mortality for hospitalized patients given the drugs, there were "some associated safety signals in the clinical laboratory findings" of an associated trial.
WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.
- OnePlus users express shock over uninstallable Facebook bloatware, company says it ensures 'higher battery efficiency'
- Samsung topples Xiaomi as the overall mobile phone leader in India
- Best 6GB RAM phones in India
- Delhi HC allows DU to conduct online Open Book Exams
- Best baby books for every parent